Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.

Authors :: Fargeot G
Dupel-Pottier C
Stephant M
Lazarovici J
Thomas L
Mouthon-Reignier C
Riad B
Carde P
Berzero G
Tafani C
Nicolas W
Viala K
Maisonobe T
Lenglet T
Wang A
Magy L
Bihan K
Gaspar N
Adams D
Echaniz-Laguna A
Cauquil C
Psimaras D
Source :: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2020 Jul; Vol. 91 (7), pp. 786-788. Date of Electronic Publication: 2020 Apr 23.
Publication Year :: 2020
Abstract: Competing Interests: Competing interests: JL has received research grants and personal fees from Takeda pharmaceutical company. GF, CD-P, MS, LT, CM-R, BR, GB, CT, WN, KV, TM, TL, AW, LM, KB, NG, DA, AE-L, CC and DP declare that they have no conflict of interest.

Subjects :: Adult
Aged
Antineoplastic Agents therapeutic use
Brentuximab Vedotin therapeutic use
Female
Hodgkin Disease drug therapy
Humans
Lymphoma, Non-Hodgkin drug therapy
Male
Middle Aged
Young Adult
Antineoplastic Agents adverse effects
Brentuximab Vedotin adverse effects
Guillain-Barre Syndrome chemically induced
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating chemically induced

Full Text Access

Tools